DETROIT, April 24,
2024 /PRNewswire/ -- In observance of Parkinson's
Disease Awareness Month, Quest Research Institute (Quest), a site
within Alcanza Clinical Research's network located in
Detroit, emphasizes the importance
of raising awareness about Parkinson's disease (PD), recognizing
its symptoms, and understanding the available clinical research
avenues for patients.
With over two decades of experience and a broad spectrum of
studies exploring investigational therapies and interventions,
Quest is actively contributing to PD research. Kara Bardram, Quest's Site Director, underscores
Alcanza's commitment to advancing scientific knowledge and
enhancing patient care, emphasizing the significance of PD
research, especially in Michigan,
where over 35,000 individuals are affected by the disease. Notably,
across the network, other sites are also actively engaged in
conducting PD trials, reflecting a coordinated effort within
Alcanza to address Parkinson's Disease comprehensively.
Recent research published in The Journal of American Medical
Association's (JAMA) Network highlights progress in the PD field,
such as a biomarker skin biopsy test funded by the Michael J. Fox
Foundation for Parkinson's Research (MJFF). Quest has conducted
numerous studies utilizing this test, aiding in the diagnosis of PD
by detecting alpha synuclein, a marker for the disease in addition
to other studies funded by the MJFF.
"Research like the skin biopsy test is important as it has
already migrated to use in clinical practice – it helps clinicians
differentiate between PD and other similar neurodegenerative
disorders," said Dr. Aaron
Ellenbogen, Quest's Medical Director, who has been using
this skin test in clinical practice for more than a year. "Without
people willing to participate in studies, tests like this would not
be able to be developed."
Parkinson's disease remains a progressive neurological condition
that significantly impacts movement and presents challenges for
patients and healthcare providers worldwide. Despite advancements
in treatment options, further research is imperative to address the
unmet needs in PD care.
Regarding Alcanza Clinical Research and Quest
Research Institute:
Alcanza operates as a unified network of research centers
committed to diminishing obstacles to clinical research
involvement, particularly among marginalized patient demographics.
The network encompasses 22 dedicated research centers, including
Quest, and several additional sites integrated within specialty
clinics. Quest focuses on Phase I-IV trials spanning diverse
therapeutic fields, with a particular emphasis on Alzheimer's
disease, Parkinson's disease, and related movement disorders.
Contact:
Alcanza Public Relations
pr@alcanzaclinical.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alcanzas-quest-research-institute-advocates-awareness-and-education-during-parkinsons-disease-awareness-month-provides-updates-on-recent-parkinsons-disease-research-302126194.html
SOURCE Alcanza Clinical Research